Skip to main content
PMC home page
Clinical and Experimental Immunology logoLink to Clinical and Experimental Immunology
. 1978 Dec;34(3):311–317.

Plasma thymic hormone activity in patients with chronic mucocutaneous candidiasis

C H Kirkpatrick, Lynn E Greenberg, S W Chapman, G Goldstein, Verna M Lewis, J J Twomey
PMCID: PMC1537547  PMID: 743805

Abstract

To further characterize the immunological abnormalities in patients with chronic mucocutaneous candidiasis, the thymic hormone activity in their plasma was measured. Of the sixteen patients in the study, seven had chronic diffuse candidiasis, five had candidiasis with endocrinopathies and four had candidiasis with thymoma. Only one patient, an anergic child with chronic diffuse candidiasis had severe deficiency of plasma thymic hormone activity. Two patients, a woman with candidiasis and multiple endocrinopathies and an elderly man with metastatic epithelial thymoma had supranormal values.

These studies indicate that the immunological deficit in most patients with these forms of chronic mucocutaneous candidiasis is not due to deficiency of a thymic inductive activity and suggest that an intrinsic defect exists in the maturation of antigen-responsive lymphoid cells.

Full text

PDF
311

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Ballow M., Hyman L. R. Combination immunotherapy in chronic mucocutaneous candidiasis. Synergism between transfer factor and fetal thymus tissue. Clin Immunol Immunopathol. 1977 Nov;8(3):504–512. doi: 10.1016/0090-1229(77)90014-9. [DOI] [PubMed] [Google Scholar]
  2. Blizzard R. M., Gibbs J. H. Candidiasis: studies pertaining to its association with endocrinopathies and pernicious anemia. Pediatrics. 1968 Aug;42(2):231–237. [PubMed] [Google Scholar]
  3. Chapman S. W., Kirkpatrick C. H. The two-step leukocyte migration inhibition factor (LIF) assay. Its use in evaluation of cellular immune function in patients with immunodeficiency diseases. Cell Immunol. 1978 Apr;37(1):209–220. doi: 10.1016/0008-8749(78)90188-0. [DOI] [PubMed] [Google Scholar]
  4. Clausen J. E. Migration inhibitory effect of cell-free supernatants from tuberculin-stimulated cultures of human mononuclear leukocytes demonstrated by two-step MIF agarose assay. J Immunol. 1973 Feb;110(2):546–551. [PubMed] [Google Scholar]
  5. Goldstein G. Editorial: "Myasthenia gravis" or the autoimmunity, thymic disease, neuromuscular block poser. West J Med. 1975 Aug;123(2):138–139. [PMC free article] [PubMed] [Google Scholar]
  6. Hermans P. E., Ulrich J. A., Markowitz H. Chronic mucocutaneous candidiasis as a surface expression of deep-seated abnormalities. Report of a syndrome of superficial candidiasis, absence of delayed hypersensitivity and aminoaciduria. Am J Med. 1969 Oct;47(4):503–519. doi: 10.1016/0002-9343(69)90181-8. [DOI] [PubMed] [Google Scholar]
  7. Jondal M., Holm G., Wigzell H. Surface markers on human T and B lymphocytes. I. A large population of lymphocytes forming nonimmune rosettes with sheep red blood cells. J Exp Med. 1972 Aug 1;136(2):207–215. doi: 10.1084/jem.136.2.207. [DOI] [PMC free article] [PubMed] [Google Scholar]
  8. Kirkpatrick C. H., Ottenson E. A., Smith T. K., Wells S. A., Burdick J. F. Reconstitution of defective cellular immunity with foetal thymus and dialysable transfer factor. Long-term studies in a patient with chronic mucocutaneous candidiasis. Clin Exp Immunol. 1976 Mar;23(3):414–428. [PMC free article] [PubMed] [Google Scholar]
  9. Kirkpatrick C. H., Rich R. R., Bennett J. E. Chronic mucocutaneous candidiasis: model-building in cellular immunity. Ann Intern Med. 1971 Jun;74(6):955–978. doi: 10.7326/0003-4819-74-6-955. [DOI] [PubMed] [Google Scholar]
  10. Kirkpatrick C. H., Rich R. R., Graw R. G., Jr, Smith T. K., Mickenberg I., Rogentine G. N. Treatment of chronic mucocutaneous moniliasis by immunologic reconstitution. Clin Exp Immunol. 1971 Dec;9(6):733–748. [PMC free article] [PubMed] [Google Scholar]
  11. Kirkpatrick C. H., Smith T. K. Chronic mucocutaneous candidiasis: immunologic and antibiotic therapy. Ann Intern Med. 1974 Mar;80(3):310–320. doi: 10.7326/0003-4819-80-3-310. [DOI] [PubMed] [Google Scholar]
  12. Lehner T., Wilton J. M., Ivanyi L. Immunodeficiencies in chronic muco-cutaneous candidosis. Immunology. 1972 May;22(5):775–787. [PMC free article] [PubMed] [Google Scholar]
  13. Levy R. L., Bach M. L., Huang S., Bach F. H., Hong R., Ammann A. J., Bortin M., Kay H. E. Thymic transplantation in a case of chronic mucocutaneous candidiasis. Lancet. 1971 Oct 23;2(7730):898–900. doi: 10.1016/s0140-6736(71)92503-7. [DOI] [PubMed] [Google Scholar]
  14. Lewis V., Twomey J. J., Goldstein G., O'Reilly R., Smithwick E., Pahwa R., Pahwa S., Good R. A., Schulte-Wisserman H., Horowitz S. Circulating thymic-hormone activity in congenital immunodeficiency. Lancet. 1977 Sep 3;2(8036):471–475. doi: 10.1016/s0140-6736(77)91601-4. [DOI] [PubMed] [Google Scholar]
  15. Louria D. B., Shannon D., Johnson G., Caroline L., Okas A., Taschdjian C. The susceptibility to moniliasis in children with endocrine hypofunction. Trans Assoc Am Physicians. 1967;80:236–249. [PubMed] [Google Scholar]
  16. Montes L. F., Ceballos R., Cooper M. D., Bradley M. N., Bockman D. E. Chronic mucocutaneous candidiasis, myositis, and thymoma. A new triad. JAMA. 1972 Dec 25;222(13):1619–1623. [PubMed] [Google Scholar]
  17. REIF A. E., ALLEN J. M. THE AKR THYMIC ANTIGEN AND ITS DISTRIBUTION IN LEUKEMIAS AND NERVOUS TISSUES. J Exp Med. 1964 Sep 1;120:413–433. doi: 10.1084/jem.120.3.413. [DOI] [PMC free article] [PubMed] [Google Scholar]
  18. Rocklin R. E., Meyers O. L., David J. R. An in vitro assay for cellular hypersensitivity in man. J Immunol. 1970 Jan;104(1):95–102. [PubMed] [Google Scholar]
  19. Snyderman R., Altman L. C., Frankel A., Blaese R. M. Defective mononuclear leukocyte chemotaxis: a previously unrecognized immune dysfunction. Studies in a patient with chronic mucocutaneous candidiasis. Ann Intern Med. 1973 Apr;78(4):509–513. doi: 10.7326/0003-4819-78-4-509. [DOI] [PubMed] [Google Scholar]
  20. Spitler L. E., Levin A. S., Fudenberg H. H. Transfer factor II: results of therapy. Birth Defects Orig Artic Ser. 1975;11(1):449–456. [PubMed] [Google Scholar]
  21. Twomey J. J., Goldstein G., Lewis V. M., Bealmear P. M., Good R. A. Bioassay determinations of thymopoietin and thymic hormone levels in human plasma. Proc Natl Acad Sci U S A. 1977 Jun;74(6):2541–2545. doi: 10.1073/pnas.74.6.2541. [DOI] [PMC free article] [PubMed] [Google Scholar]
  22. Twomey J. J., Lazar S., Rocklin R. E. Human cells required for macrophage migration inhibitory factor (MIF) production. Clin Immunol Immunopathol. 1977 Nov;8(3):396–404. doi: 10.1016/0090-1229(77)90004-6. [DOI] [PubMed] [Google Scholar]
  23. Twomey J. J., Waddell C. C., Krantz S., O'reilly R., L'esperance P., Good R. A. Chronic mucocutaneous candidiasis with macrophage dysfunction, a plasma inhibitor, and co-existent aplastic anemia. J Lab Clin Med. 1975 Jun;85(6):968–977. [PubMed] [Google Scholar]
  24. Valdimarsson H., Higgs J. M., Wells R. S., Yamamura M., Hobbs J. R., Holt P. J. Immune abnormalities associated with chronic mucocutaneous candidiasis. Cell Immunol. 1973 Mar;6(3):348–361. doi: 10.1016/0008-8749(73)90035-x. [DOI] [PubMed] [Google Scholar]

Articles from Clinical and Experimental Immunology are provided here courtesy of British Society for Immunology

RESOURCES